Vaxart Oral COVID-19 Vaccine Joins Trump’s “Warp Speed,” Ramps Up Manufacturing Capacity

Vaxart’s room temperature stable tablet vaccine has been selected for a non-human primate (NHP) challenge study organized and funded by Operation Warp Speed. The study is designed to demonstrate the efficacy of Vaxart’s COVID-19 vaccine candidate, based on the company’s Vector-Adjuvant-Antigen Standardized Technology (VAAST™) Platform.